Abstract: Hepatectomy is the main optimal curative treatment of hepatocellular carci-noma (HCC) to achieve long‑term survival. However, most patients in China do not fulfill the criteria for surgery due to the intermediate-advanced stage of HCC at their initial diagnosis. With the promising advances in locoregional and systematic therapies, development of targeted drugs, success of immunotherapy, as well as the emergence of the therapeutic alliance, conversion therapy has well developed nowadays and become a hotspot in recent years. A part of unresectable HCC patients have afforded sequent radical surgery opportunities and prolonged the overall survival through improving liver function, increasing the residual liver volume, and minimizing tumor volume. At present, target therapy combined immunotherapy, local therapy combined systemic therapy are commonly used and widely applicable conversion therapy modes in China. Based on expansion of conversion therapy concepts, more high‑level evidences are needed to exploit the full potential of conversion treatment strategies, accurately select candidates, determine the timing of surgery, improve conversion rate, guarautee the safety and long‑term efficacy, which requires further investigation and research.